UBS Group
CBAY

UBS Group’s Cymabay Therapeutics CBAY Stock Holding History

UBS Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,900
Closed -$371K – 10254
2023
Q3 		$371K Buy
+24,900
New +$330K ﹤0.01% 4885
2023
Q2 		– Sell
-3,600
Closed -$31.4K – 10006
2023
Q1 		$31.4K Buy
+3,600
New +$28.8K ﹤0.01% 6765

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's CBAY Position: Q1 2024 in Review

UBS Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 138,241 shares — an estimated $3.27M sold.

UBS Group first reported a position in CBAY in Q4 2014 and held it in 33 quarters. The position peaked at $3.27M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • UBS Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 138,241 Cymabay Therapeutics shares in Q1 2024, an estimated $3.27M.
  • UBS Group first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 33 quarters.
  • UBS Group's Cymabay Therapeutics position peaked at $3.27M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.